London, 31 July 2005 EMEA/252976/2005

#### COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

# MONTHLY REPORT OF APPLICATION PROCEDURES, GUIDELINES AND RELATED DOCUMENTS

The CVMP Monthly Report includes statistical data for the current year and the previous two ones on Initial Evaluations, Scientific Advice, Variations, Line Extensions, Renewals, MRLs Initial Evaluations and MRLs Extensions/Modifications and Arbitration and Referral procedures.

In addition, the report includes a summary table of the opinions issued by the CVMP in the current year and a list of adopted Guidelines and other public documents.

The CVMP Monthly Report will be updated at the end of each month.

Peter G.H. Jones

Head, Veterinary Medicines Evaluation Unit

The Monthly Report, the Press Release and other documents are available on the Internet at the following address: <a href="https://www.emea.eu.int">www.emea.eu.int</a>

#### **Initial Evaluation**<sup>a</sup>

	1995-2002	2003	2004	2005	Total
<b>Full Applications</b>	50	10	7	5	72
Abridged Applications	1	1	1	0	3
Withdrawals	8	1	1	0	10
Positive opinions	38	3	10	5	56
Negative opinions	0	0	0	0	0

#### **Scientific Advice**

	1995-2002	2003	2004	2005	Total
Requests received	20	2	5	6	33

<sup>&</sup>lt;sup>a</sup> Applications submitted and validated: overall total 75 applications (full + abridged), comprising 39 immunologicals and 36 pharmaceuticals.

Negative opinions: in case of appeals, the opinion will not be counted twice.

## **Extensions (Annex II applications)**

	1995-2002	2003	2004	2005	Total
Applications submitted	32	2	5	8	47 <sup>b</sup>
Withdrawals	1	0	0	0	1
Positive opinions	15	6	3	2	26
Negative opinions	0	0	0	0	0

#### Variations

	1995-2002	2003	2004	2005	Total
Type IA	99	48	14	7	187
Type IB	99	40	5	14	16/
Transfers	2	2	1	1	6
Type II	37	12	16	17	82

# Renewals of marketing authorisations

	1995-2002	2003	2004	2005	Total
Applications submitted	7	4	7	4	22
Positive opinions	5	4	5	6	20
Negative opinions	0	0	0	0	0

## **Arbitrations and Community Referrals**

	1995-2003	2003	2004	2005	Total
Submitted	7	1	2	0	10

Page 2 of 8 © EMEA 2005

<sup>&</sup>lt;sup>b</sup> Applications submitted and validated: overall total 47 line extensions, comprising 8 immunologicals and 39 pharmaceuticals; one opinion can cover a number of extensions.

## Establishment of maximum residue limits (MRLs) for new substances

	1995-2002	2003	2004	2005	Total
Applications submitted	50	1	6	2	59
Withdrawals	5	0	0	0	5
Positive opinions c	36	1	4	3	44
Negative opinions d	5	0	1	0	6

#### **Extensions / Modifications of MRLs**

	1995-2002	2003	2004	2005	Total
Applications submitted	73	7	7	4	91
Withdrawals	4	0	0	0	4
Positive opinions <sup>c</sup>	79	6	8	6	99
Negative opinions d	5	0	0	0	5

Page 3 of 8 © EMEA 2005

<sup>&</sup>lt;sup>c</sup> Including opinions recommending definitive MRLs for substances with previously provisional maximum residue limits <sup>d</sup> Including one opinion concluding that final MRL could not be established for a substance with provisional maximum residue limits previously established

# **CVMP Opinions in 2005 on Medicinal Products for Veterinary Use**

# Positive Opinions

Product  Brand name  INN Part A or B	Marketing authorisation holder	Therapeutic area  Target species  Summary of indication	EMEA/CVMP  Validation Opinion Active time Clock stop	European Commission Opinion received Date of decision Notification Official Journal
<ul><li>Naxcel</li><li>Ceftiofur</li><li>Part B</li></ul>	Pfizer	<ul><li>Pigs</li><li>Respiratory disease</li></ul>	• 12.11.2002 • 11.01.2005 • 210 • 506	<ul> <li>15.02.2005</li> <li>19.05.2005</li> <li>24.05.2005</li> <li>OJ C 153, 24.06.2005, p.5</li> </ul>
<ul><li>Profender</li><li>Emodepside praziquantel</li><li>Part B</li></ul>	Bayer Health Care	■ Cats ■ Antiparasitic	<ul> <li>16.03.2004</li> <li>18.05.2005<sup>f</sup></li> <li>204</li> <li>155</li> </ul>	• 16.06.2005 • •
<ul><li>Equilis     Prequenza-Te</li><li>Vaccine</li><li>Part B</li></ul>	Intervet	<ul><li>Horses</li><li>Equine influenza and tetanus</li></ul>	13.01.2004 13.04.2005 183 273	• 27.05.2005 • 08.07.2005 •
<ul><li> Equilis Prequenza</li><li> Vaccine</li><li> Part B</li></ul>	Intervet	<ul><li>Horses</li><li>Immunity against influenza</li></ul>	13.01.2004 13.04.2005 183 273	• 27.05.2005 • 08.07.2005 •
<ul><li> Equilis Te</li><li> Vaccine</li><li> Part B</li></ul>	Intervet	<ul><li>Horses</li><li>Immunity against tetanus</li></ul>	13.01.2004 13.04.2005 183 273	• 27.05.2005 • 08.07.2005 •
<ul> <li>Metacam 0.5         mg/ml oral         suspension for         dogs (extension         new strength)</li> </ul>	Boehringer Ingelheim Vetmedica GmbH	<ul><li>Dogs</li></ul>	<ul> <li>05.08.2004</li> <li>18.05.2005</li> <li>187</li> <li>99</li> </ul>	• 01.06.2005 • •
<ul> <li>Novem 5mg/ml (extension to new targer species)</li> </ul>	Boehringer Ingelheim Vetmedica GmbH	<ul><li>Pigs</li><li>Musculo-skeletal disorder</li></ul>	• 15.03.2005 • 15.06.2005 • 92 • 0	• • •

\_

 $<sup>^{\</sup>rm f}$  Confirmation of positive opinion CVMP dated 09.03.2005

# **CVMP Opinions in 2005 on establishment of MRLs for new substances**

#### Positive Opinions

Substance INN	Toward marine		I
Substance INN	Target species	EMEA/CVMP  Validation Opinion Active time Clock stop	<ul> <li>European Commission</li> <li>Opinion received</li> <li>Date of regulation</li> <li>Official Journal</li> </ul>
■ Phenoxymethylpenicillin (extension)	Poultry	<ul> <li>12.02.2004</li> <li>12.01.2005</li> <li>120 days</li> <li>214 days</li> </ul>	• 02.02.2005 • •
Thiamphenicol (extension)	Pigs	<ul> <li>19.06.2003</li> <li>12.01.2005</li> <li>119 days</li> <li>453 days</li> </ul>	• 02.02.2005 • •
■ Phoxim (extension)	Chickens	<ul> <li>17.10.2002</li> <li>12.01.2005</li> <li>180 days<sup>e</sup></li> <li>637 days</li> </ul>	• 02.02.2005 • •
Oxolinic acid (extension)	Cattle (extrapolated to all food producing species)	<ul> <li>11.09.2003</li> <li>09.02.2005</li> <li>180 days<sup>e</sup></li> <li>516 days</li> </ul>	• 11.03.2005 • •
<ul> <li>Acetylisovaleryltylosin (extension)</li> </ul>	Poultry	<ul> <li>15.04.2004</li> <li>09.03.2005</li> <li>179 days<sup>e</sup></li> <li>149 days</li> </ul>	• 06.04.2005 • •
■ Fluazuron	Cattle	<ul> <li>09.12.2004</li> <li>09.03.2005</li> <li>90 days</li> <li>0 days</li> </ul>	• 06.04.2005 •
■ Firocoxib	Horses	<ul> <li>15.07.2004</li> <li>13.07.2005</li> <li>120 days</li> <li>243 days</li> </ul>	•
Spruce-tips extract	All food producing	<ul> <li>16.01.2004</li> <li>13.07.2005</li> <li>117 days</li> <li>426 days</li> </ul>	• •
■ Tosylchloramide Sodium (extension)	Horses	<ul> <li>14.04.2005</li> <li>13.07.2005</li> <li>90 days</li> <li>0 days</li> </ul>	• •

-

 $<sup>^{\</sup>rm e}$  Active time for the evaluation of the initial application and submission of responses to outstanding issues following the establishment of provisional MRLs.

## **Arbitrations and Community Referrals in 2005**

#### Community harmonisation and pharmacovigilance referrals

Type of referral	Date of CVMP opinion	International non-proprietary name (INN)
-	-	-

## **Guidelines and Working Documents in 2005**

#### **CVMP Safety Working Party**

Reference number	Document title	Status
EMEA/CVMP/543/03-FINAL	Guideline on user safety for pharmaceutical veterinary medicinal products	Adopted January 2005 (coming into effect 13 July 2005)
EMEA/CVMP/209865/2004	Overview of comments received on draft Guideline on Injection Site Residues (EMEA/CVMP/542/03)	Adopted January 2005
EMEA/CVMP/41180/2005	Summary of the comments received on draft guideline on user safety for pharmaceutical veterinary medicinal products (EMEA/CVMP/543/03-CONSULTATION)	Adopted April 2005
EMEA/CVMP/66781/2005- CONSULTATION	Guideline on Safety and Residue Data Requirements for Veterinary Medicinal Products intended for Minor Uses and Minor Species	Released for consultation April 2005 (end of consultation 31 October 2005)
EMEA/CVMP/SWP/122154/2005- CONSULTATION	Concept Paper on a Guideline on the Assessment of pharmacological/pharmacodynamic data to establish a pharmacological ADI	Released for consultation May 2005 (end of consultation 31 July 2005)
CVMP/VICH/645/01-Rev.1-FINAL	VICH Topic GL 28: "Studies to evaluate the Safety of Residues of Veterinary Drugs in Human Food: Carcinogenicity Testing	Adopted May 2005

#### **CVMP Scientific Advisory Group on Antimicrobials**

Reference number	Document title	Status
EMEA/CVMP/1034/04-Consultation	Concept paper on further guidance on interpretation of the data from VICH GL27	Released for consultation March 2005 (end of consultation 9 June 2005)
EMEA/CVMP/67951/2005- CONSULTATION	Concept Paper on revision of the current guideline on the SPC for antimicrobial products (EMEA/CVMP/612/01-FINAL)	Released for consultation June 2005 (end of consultation 31 August 2005)

Page 6 of 8 © EMEA 2005

# Joint CHMP/CVMP Quality Working Party

Reference number	Document title	Status
EMEA/CVMP/511/03 Annex to: EMEA/CVMP/VICH/502/99	Annexes to Guideline on Impurities Residual Solvents	Adopted January 2005
EMEA/CVMP/134/02-Rev.1	Guideline on Active substance Master File Procedure	Adopted April 2005
EMEA/CVMP/QWP/114420/2005- CONSULTATION	Concept Paper on the development of a Guideline on Parametric Release	Released for consultation April 2005 (end of consultation 31 July 2005)
EMEA/CVMP/QWP/128710/2004- CONSULTATION	Guideline on Quality Data Requirements for Veterinary Medicinal Products intended for Minor Uses and Minor Species	Released for consultation April 2005 (end of consultation 31 October 2005)
EMEA/CVMP/205/04-FINAL	Guideline on plastic primary packaging materials	Adopted May 2005 (coming into effect 1 December 2005)
EMEA/CVMP/373/04-FINAL	Guideline on stability testing for applications for variations to a marketing authorisation	Adopted May 2005 (coming into effect 1 December 2005)
EMEA/CVMP/815/00-Rev.1	Guideline on Specifications: Test procedures and acceptance criteria for Herbal Substances, Herbal Preparations and Herbal Medicinal Products/Traditional Herbal Medicinal Products	Released for consultation June 2005 (end of consultation 15 September 2005)
CVMP/VICH/837/99-Rev.1- CONSULTATION	VICH Topic GL10(R) Quality: Impurities in new veterinary drug substances	Released for consultation June 2005 (end of consultation 1 September 2005)
CVMP/VICH/838/99-Rev.1- CONSULTATION	VICH Topic GL11(R) Quality: Impurities in new veterinary medicinal products	Released for consultation June 2005 (end of consultation 1 September 2005)
EMEA/CVMP/814/00-Rev.1	Guideline on Quality of Herbal Medicinal Products/Traditional Herbal Medicinal Product	Released for consultation July 2005 (end of consultation 30 September 2005)

# CVMP Pharmacovigilance Working Party (PhVWP-V)

Reference number	Document title	Status
EMEA/CVMP/900/03-FINAL	Guideline on Strategy for Triggering Investigations preceding Regulatory Actions by EU Competent Authorities	Adopted April 2005 (coming into effect 1 November 2005)
EMEA/CVMP/PhVWP/110607/2005- CONSULTATION	Veterinary Pharmacovigilance in the EU – A simple guide to reporting adverse reactions	Released for consultation April 2005 (end of consultation 18 October 2005)
EMEA/CVMP/893/04	Guideline on EU Veterinary Suspected Adverse Reaction report form for veterinarians and health professionals	Adopted June 2005
EMEA/CVMP/SOP/693/99-Rev.1	Procedure for Management of 15-day Suspected Adverse Reaction (SAR) reports to a centrally authorised veterinary medicinal product	Adopted June 2005
EMEA/CVMP/PhVWP/145320/2005- CONSULTATION	Concept Paper on a Periodic Safety Update Report (PSUR) assessment guideline for veterinary medicinal products	Released for consultation July 2005 (end of consultation 30 September 2005)

# **CVMP Efficacy Working Party**

Reference number	Document title	Status
EMEA/CVMP/EWP/117899/2004- CONSULTATION	Guideline on Efficacy and Target Animal Safety Data Requirements for Veterinary Medicinal Products intended for Minor Uses and Minor Species	Released for consultation April 2005 (end of consultation 31 October 2005)
EMEA/CVMP/EWP/79590/2005- CONSULTATION	Concept Paper on Dossier Requirements for Oncology Porducts	Released for consultation June 2005 (end of consultation 30 September 2005)

## **CVMP Immunologicals Working Party**

Reference number	Document title	Status
EMEA/CVMP/743/00-Rev.1	Revised guideline on requirements and controls applied to bovine serum used in the production of immunological veterinary medicinal products	Adopted July 2005 (coming into effect 1 January 2006)

#### **CVMP General**

Reference number	Document title	Status
EMEA/CVMP/115769/2005	Guideline For An Assessor Preparing Assessment Reports For Veterinary Medicinal Products	Adopted May 2005

Page 8 of 8 © EMEA 2005